From the garage to a COVID-19 vaccine lab
When local synthetic antibiotics developer Recce Pharmaceuticals announced they had entered into an antiviral Sars-CoV-2...
When local synthetic antibiotics developer Recce Pharmaceuticals announced they had entered into an antiviral Sars-CoV-2...
Prescient Therapeutics (ASX: PTX) Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the...
PTX has acquired the exclusive global licence to a universal immune receptor (UIR) platform from...
We maintain our Buy rating and are increasing our price target to A$0.20 from A$0.16...
We maintain our Buy rating and are increasing our price target to A$0.16from A$0.09. The...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.